Read More

Canadian Financing: PharmAla Biotech Offers Non-Brokered Private Placement Up To $3.76M

MDXX-class molecules biotech company PharmAla Biotech Holdings Inc. (OTCMKTS: PMBHF) has announced a non-brokered private placement of a minimum of 3.3 million units and a maximum of 16.6 million of its units at a price of $0.22 (CA$0.30) each, corresponding to aggregate gross proceeds of minimum $752,300 (CA$1 million,) and maximum $3.76 (CA$5 million.) 

PMBHF

Read More

Agile Therapeutics Announces New Agreement With VitaCare Prescription Services To Improve Access To Twirla; Expanding Commercial Reach Through Partnerships Continues To Drive Company’s Belief In Achieving 2023 Net Revenue In The Range Of $25M-$30M

Agile Plans to Increase Twirla prescriptions filled through telemedicine platforms that utilize vitaCare, such as Twentyeight Health™ Partnership Expected to Augment Future Growth in the Retail Channel, the

AGRX